Alexion Settles Bribery Charges for $21.5 Million

Massachusetts-based Alexion Pharmaceuticals has agreed to pay $21.5 million to settle charges that it violated the Foreign Corrupt Practices Act.

The Securities and Exchange Commission (SEC) charged the company’s subsidiaries in Turkey and Russia with allegedly bribing government officials to boost sales of its immunosuppressive drug Soliris (eculizumab).

The SEC also charged the company’s subsidiaries in Brazil and Colombia for inaccurate financial records of payments to patient advocacy organizations.